Earnings summaries and quarterly performance for Nutex Health.
Executive leadership at Nutex Health.
Board of directors at Nutex Health.
Research analysts who have asked questions during Nutex Health earnings calls.
GM
Gene Mannheimer
Freedom Capital Markets
5 questions for NUTX
Also covers: CCSI, FCHS, ICAD +3 more
AV
Anthony Vendetti
Maxim Group
4 questions for NUTX
Also covers: AEMD, AGFY, BHST +19 more
WS
William Sutherland
The Benchmark Company
4 questions for NUTX
Also covers: AMN, AONC, BEAT +10 more
BS
Bradford Seagraves
North Bank Capital
3 questions for NUTX
BS
Bill Sutherland
The Benchmark Company LLC
2 questions for NUTX
Also covers: AMED, ATIP, BEAT +7 more
CB
Carl Burns
Analyst
2 questions for NUTX
Also covers: TLSI
CB
Carl Byrnes
Northland Capital Markets
1 question for NUTX
Also covers: ALVO, BLFS, BWAY +6 more
Joshua Cohen
Westbury Capital
1 question for NUTX
Thomas McGovern
Maxim Group
1 question for NUTX
Also covers: BRFH, NEPH, UGRO +2 more
Tom McGovern
Maxim Group
1 question for NUTX
Recent press releases and 8-K filings for NUTX.
Nutex Health Extends Share Repurchase Plan
NUTX
Share Buyback
- Nutex Health Inc.'s Board of Directors has approved an extension of its previously authorized stock repurchase program.
- The original program, announced on August 14, 2025, authorized the repurchase of up to $25.0 million of the Company's common stock over a six-month period, commencing upon the filing of the Form 10-Q for the quarter ended June 30, 2025.
- The Board has extended the program through March 31, 2026, with the repurchase plan scheduled to go into effect on or about December 4, 2025, under Rule 10b-18 and a Rule 10b5-1 trading plan.
- The purpose of the share repurchase program is to increase shareholder value and offset dilution from the issuance of additional shares related to stock compensation obligations for under-construction and ramping hospitals.
Dec 4, 2025, 10:30 AM
Nutex Health Reports Strong Q3 2025 Financial Performance and Operational Growth
NUTX
Earnings
Financial Restatement
New Projects/Investments
- Nutex Health reported strong Q3 2025 financial results, with revenue reaching $267.8 million, a 240% increase from Q3 2024, and net income of $55.4 million compared to an $8.8 million loss in the prior year.
- Profitability significantly improved, with Adjusted EBITDA growing to $98.5 million in Q3 2025 from $9.7 million in Q3 2024, and diluted EPS of $7.76 compared to a loss of $1.72 per share.
- The balance sheet strengthened, showing cash and cash equivalents of $166 million as of September 30, 2025, up from $40.6 million at year-end 2024, and operating cash flow of $177.7 million for the first nine months of 2025.
- Operationally, total patient visits increased by 11% to 46,232 in Q3 2025, and the company is on track to open three new hospitals in 2025, with three to four planned for 2026.
- The restatement of 2024 and Q1 2025 financials was completed with minor, non-material adjustments, and the company is seeing increased engagement from payers for in-network contracts following successful Independent Dispute Resolution (IDR) outcomes.
Dec 2, 2025, 3:30 PM
Nutex Health Reports Strong Q3 2025 Financial Results and Operational Growth
NUTX
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Nutex Health reported strong Q3 2025 financial results, with revenue reaching $267.8 million, a 240% increase from Q3 2024, and adjusted EBITDA growing to $98.5 million from $9.7 million in the prior year.
- Net income for Q3 2025 was $55.4 million, compared to an $8.8 million loss in Q3 2024, resulting in diluted EPS of $7.76 per share.
- The company's balance sheet remains strong, with cash increasing to $166 million as of September 30, 2025, from $40.6 million at year-end 2024, and operating cash flow totaling $177.8 million through the first three quarters of 2025.
- Operationally, total patient visits increased by 11% to 46,232 in Q3 2025 compared to Q3 2024, and the company is on track to open three new hospitals in 2025, with Red River already open and Houston and St. Louis scheduled by year-end.
Dec 2, 2025, 3:30 PM
Nutex Health Reports Strong Q3 and Nine-Month 2025 Financial Results, Regains Nasdaq Compliance
NUTX
Earnings
Revenue Acceleration/Inflection
Delisting/Listing Issues
- Nutex Health Inc. reported total revenue of $723.6 million for the first nine months of 2025, representing a 225.5% increase compared to the same period in 2024.
- For the first nine months of 2025, the company achieved net income attributable to Nutex Health Inc. of $59.0 million, or diluted income per share of $8.87, a significant improvement from a net loss of $9.5 million and loss per share of $1.91 in the prior year.
- Adjusted EBITDA for the first nine months of 2025 increased by 1408.6% to $243.0 million.
- For the third quarter ended September 30, 2025, Nutex Health reported total revenue of $267.8 million and net income attributable to Nutex Health of $55.4 million.
- On November 19, 2025, Nutex Health Inc. announced it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Form 10-Q for the period ended June 30, 2025.
Nov 19, 2025, 9:30 PM
Nutex Health Inc. Reports Strong Q3 and Year-to-Date 2025 Financial Results and Regains Nasdaq Compliance
NUTX
Earnings
Revenue Acceleration/Inflection
Delisting/Listing Issues
- Nutex Health Inc. reported total revenue of $267.8 million for the three months ended September 30, 2025, a 239.9% increase compared to the same period in 2024, and $723.6 million for the first nine months of 2025, a 225.5% increase year-over-year.
- The company achieved net income attributable to Nutex Health Inc. of $55.4 million for Q3 2025 and $59.0 million for the first nine months of 2025, a significant improvement from net losses in the prior year periods.
- Adjusted EBITDA for Q3 2025 was $98.5 million, and for the first nine months of 2025, it was $243.0 million, representing substantial increases over the prior year.
- As of September 30, 2025, Nutex Health Inc. had cash and cash equivalents of $166.0 million.
- On November 19, 2025, Nutex Health Inc. regained compliance with Nasdaq Listing Rule 5250(c)(1) regarding the timely filing of periodic reports.
Nov 19, 2025, 9:07 PM
Nutex Health Reports Q2 and H1 2025 Financial Results and Share Repurchase Program
NUTX
Earnings
Share Buyback
Revenue Acceleration/Inflection
- Nutex Health reported total revenue of $455.8 million for the first half of 2025, an increase of 217.5% compared to the first half of 2024.
- The company achieved net income attributable to Nutex Health of $3.5 million for the first half of 2025, compared to a net loss of $0.7 million in the same period of 2024, resulting in diluted income per share of $0.55.
- Adjusted EBITDA for the first half of 2025 was $144.4 million, a significant increase from $6.4 million for the first half of 2024.
- For the three months ended June 30, 2025, total revenue increased to $244.0 million, up 220.7% from $76.1 million in the same period of 2024.
- On August 14, 2025, the Board of Directors authorized a stock repurchase program of up to $25.0 million of the Company's common stock.
Nov 18, 2025, 11:59 PM
Nutex Health Reports Restated First Quarter 2025 Financial Results
NUTX
Earnings
Financial Restatement
Revenue Acceleration/Inflection
- Nutex Health Inc. reported restated first quarter 2025 financial results, with total revenue of $211.8 million, marking a 214.0% increase from $67.5 million in Q1 2024.
- The company achieved net income attributable to Nutex Health Inc. of $21.2 million for Q1 2025, a significant improvement from a net loss of $0.4 million in Q1 2024.
- Diluted income per share rose to $3.33 for Q1 2025, compared to a loss per share of $0.08 in the prior year period.
- EBITDA increased by 624.7% to $51.5 million and Adjusted EBITDA reached $72.8 million for Q1 2025, up from $7.1 million and $(0.4) million respectively in Q1 2024.
- The restatement, primarily involving non-cash adjustments, increased net income by $6.6 million and diluted EPS by $0.77, but did not materially affect key metrics such as revenue, operating cash flow, or adjusted EBITDA.
Nov 18, 2025, 11:50 PM
Nutex Health Reports Restated 2024 Financial Results with Significant Revenue and Profit Growth
NUTX
Earnings
Financial Restatement
Share Buyback
- Nutex Health Inc. announced restated full year 2024 financial results on November 18, 2025, reporting total revenue of $479.9 million, a 93.8% increase from $247.6 million in 2023.
- For the full year 2024, the company achieved net income attributable to Nutex Health Inc. of $52.1 million (compared to a net loss of $45.8 million in 2023) and diluted income per share of $9.69 (compared to a loss per share of $10.39 in 2023).
- Adjusted EBITDA for full year 2024 was $124.1 million, marking a 1046.1% increase from $10.8 million in 2023, with net cash from operating activities at $23.2 million.
- The restatement for the year ended December 31, 2024, resulted in a nominal decrease to net income by $0.5 million and diluted earnings per share by $0.02, but had no material effect on key metrics including revenue, liquidity, operating cash flow, or adjusted EBITDA.
- Management expressed confidence in the company's financial strength and 2025 growth plan, with the CEO noting a belief that shares are undervalued and mentioning a stock repurchase program.
Nov 18, 2025, 11:26 PM
Nutex Health Reports Q2 and H1 2025 Financial Results
NUTX
Earnings
Share Buyback
Revenue Acceleration/Inflection
- Nutex Health Inc. reported strong financial growth for the first half of 2025, with total revenue increasing 217.5% to $455.8 million and Adjusted EBITDA surging 2144.2% to $144.4 million compared to the first half of 2024.
- For the first half of 2025, the company achieved net income attributable to Nutex Health Inc. of $3.5 million and diluted income per share of $0.55, a significant improvement from a net loss in the prior year period.
- As of June 30, 2025, Nutex Health held $96.7 million in cash and cash equivalents.
- The Board of Directors authorized a stock repurchase program of up to $25.0 million on August 14, 2025, to be executed over the next six months.
Nov 18, 2025, 10:00 PM
Nutex Health Inc. Reports Restated First Quarter 2025 Financial Results
NUTX
Earnings
Financial Restatement
Revenue Acceleration/Inflection
- Nutex Health Inc. reported restated first quarter 2025 financial results, with total revenue increasing 214.0% to $211.8 million for the three months ended March 31, 2025, compared to $67.5 million for the same period in 2024.
- The company achieved a net income attributable to Nutex Health Inc. of $21.2 million for Q1 2025, a significant improvement from a net loss of $0.4 million in Q1 2024, and diluted income per share of $3.33.
- The restatement for Q1 2025 involved non-cash adjustments, including classification corrections for stock-based compensation obligations and reclassification of related-party accounts payable, which resulted in an increase in net income by $6.6 million and diluted EPS by $0.77.
- Adjusted EBITDA for Q1 2025 was $72.8 million, compared to $(0.4) million for the three months ended March 31, 2024.
Nov 18, 2025, 9:54 PM
Quarterly earnings call transcripts for Nutex Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more